These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1122 related items for PubMed ID: 30935417

  • 1. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF, Lee AS.
    Cardiovasc Diabetol; 2019 Apr 01; 18(1):45. PubMed ID: 30935417
    [Abstract] [Full Text] [Related]

  • 2. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
    Connelly KA, Zhang Y, Desjardins JF, Nghiem L, Visram A, Batchu SN, Yerra VG, Kabir G, Thai K, Advani A, Gilbert RE.
    Cardiovasc Diabetol; 2020 Feb 08; 19(1):13. PubMed ID: 32035482
    [Abstract] [Full Text] [Related]

  • 3. Empagliflozin directly improves diastolic function in human heart failure.
    Pabel S, Wagner S, Bollenberg H, Bengel P, Kovács Á, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J, Fischer T, Van Linthout S, Tschöpe C, Streckfuss-Bömeke K, Hasenfuss G, Maier LS, Hamdani N, Sossalla S.
    Eur J Heart Fail; 2018 Dec 08; 20(12):1690-1700. PubMed ID: 30328645
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat.
    Younis F, Leor J, Abassi Z, Landa N, Rath L, Hollander K, Naftali-Shani N, Rosenthal T.
    J Cardiovasc Pharmacol Ther; 2018 Jul 08; 23(4):358-371. PubMed ID: 29627992
    [Abstract] [Full Text] [Related]

  • 6. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD.
    Eur J Heart Fail; 2019 Jul 08; 21(7):862-873. PubMed ID: 31033127
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, Yu X, Sun B, Chen L.
    Cardiovasc Diabetol; 2019 Feb 02; 18(1):15. PubMed ID: 30710997
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet.
    Hojná S, Malínská H, Hüttl M, Vaňourková Z, Marková I, Miklánková D, Hrdlička J, Papoušek F, Neckář J, Kujal P, Behuliak M, Rauchová H, Kadlecová M, Sedmera D, Neffeová K, Zábrodská E, Olejníčková V, Zicha J, Vaněčková I.
    Biomed Pharmacother; 2024 May 02; 174():116520. PubMed ID: 38581924
    [Abstract] [Full Text] [Related]

  • 14. Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain.
    Schauer A, Adams V, Kämmerer S, Langner E, Augstein A, Barthel P, Männel A, Fabig G, Alves PKN, Günscht M, El-Armouche A, Müller-Reichert T, Linke A, Winzer EB.
    Circ Heart Fail; 2024 Jun 02; 17(6):e011107. PubMed ID: 38847102
    [Abstract] [Full Text] [Related]

  • 15. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J, De Rosa S, Tammè L, Iaconetti C, Sorrentino S, Polimeni A, Mignogna C, Amorosi A, Spaccarotella C, Yasuda M, Indolfi C.
    Cardiovasc Diabetol; 2020 May 15; 19(1):66. PubMed ID: 32414364
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J, Klinkhammer BM, Droste P, Kappel B, Haj-Yehia E, Maxeiner S, Artati A, Adamski J, Boor P, Schütt K, Lopaschuk GD, Verma S, Marx N, Lehrke M.
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug 01; 1866(8):165807. PubMed ID: 32353614
    [Abstract] [Full Text] [Related]

  • 18. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
    Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, Szabados E, Kálai T, Hideg K, Halmosi R, Sumegi B, Toth K.
    Cardiovasc Res; 2009 Aug 01; 83(3):501-10. PubMed ID: 19443425
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.